10VA Stock Overview
A biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Immunic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$1.86 |
| 52 Week Low | US$0.90 |
| Beta | 1.88 |
| 11 Month Change | -7.33% |
| 3 Month Change | -18.65% |
| 1 Year Change | 0.27% |
| 33 Year Change | -85.56% |
| 5 Year Change | -82.49% |
| Change since IPO | -93.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 10VA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 13.1% | 1.1% | 1.3% |
| 1Y | 0.3% | -18.5% | 7.9% |
Return vs Industry: 10VA exceeded the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: 10VA underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| 10VA volatility | |
|---|---|
| 10VA Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 10VA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 10VA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 85 | Daniel Vitt | imux.com |
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
Immunic, Inc. Fundamentals Summary
| 10VA fundamental statistics | |
|---|---|
| Market cap | €102.42m |
| Earnings (TTM) | -€91.82m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs 10VA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 10VA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$96.90m |
| Earnings | -US$96.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 10VA perform over the long term?
See historical performance and comparison